Alzheimer's coverage on Peptide News Digest sits at the intersection of GLP-1 secondary indications and traditional peptide neurology programs. The Phase 3 EVOKE trial of semaglutide in Alzheimer's missed its cognitive endpoint, but a 2026 AAN living systematic review integrating Phase 2/3 trials and real-world data from 2+ million diabetics found GLP-1 use was associated with 20–35% lower dementia incidence versus DPP-4 or SGLT2 inhibitors.
The gap between the EVOKE failure and the registry signals matters. Several follow-on Phase 2 trials are looking at semaglutide in mild cognitive impairment (LIGHT-MCI, OxSENSE), and the broader peptide neurology space has work on neurodegenerative biomarkers and amyloid-related peptide approaches.
Stories here cover trial readouts and the registry data that contextualize them. See #neurodegeneration and #dementia for related threads.
A 2026 review published in Cell and Tissue Research (Springer Nature) synthesized the current understanding of brain peptides in Alzheimer's disease pathophysiology and therapeutic development. The review's central organizing distinction is between pathogenic peptide species (amyloid-β oligomers, tau-derived fragments) that drive neuronal dysfunction and endogenous neuropeptides that exert neuroprotective effects: neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and pituitary adenylate cyclase-activating peptide (PACAP) are the three best-characterized protective classes. Adjacent April 2026 IJMS review covers the same neuropeptide neuroprotection thesis with broader Parkinson's-disease applicability. Advances in peptide chemistry are enabling two distinct therapeutic strategies: aggregation inhibitors that prevent amyloid-β oligomerization, and receptor-selective neuropeptide analogues that recapitulate endogenous NPY/VIP/PACAP signaling with improved blood-brain-barrier penetration. The peptide-neurodegeneration thread runs parallel to the BioArctic-Lilly $800 million BrainTransporter pact (June 23, peptide-delivery focus), Insilico-SK Biopharm $2.5B AI-neuroimmune deal (June 22 BIO 2026 opening), and the NVG-291 PTPσ inhibitor that NervGen is preparing for Phase 3 in chronic SCI mid-2026.
The ELAD trial — a multicenter, randomized, double-blind, placebo-controlled Phase 2b study of liraglutide in 204 mild-to-moderate Alzheimer's disease participants — published in Nature Medicine (online December 2025) continues to drive clinical-research discussions about GLP-1s in neurodegeneration. Coming after the Phase 3 EVOKE trials' negative cognition results, ELAD's intermediate-stage findings are being parsed for endpoints, mechanisms, and biomarker patterns that may guide future trial design in this contested indication.
A comprehensive NeurologyLive review details emerging evidence for GLP-1 receptor agonists across neurological diseases including Alzheimer's, Parkinson's, multiple sclerosis, and stroke. Despite setbacks in the Phase 3 EVOKE Alzheimer's trial, ongoing trials like LIGHT-MCI and OxSENSE continue to explore neurobiological mechanisms beyond metabolic effects.
Comprehensive review examining GLP-1 receptor agonists for neurological conditions. A recent NEJM trial showed GLP-1 treatment resulted in less motor disability progression at 12 months.
A comprehensive NeurologyLive review examines evidence for repositioning GLP-1 drugs across neurological conditions. Exenatide and lixisenatide show motor benefits in Parkinson's disease, while GLP-1 agonists reduced intracranial pressure and migraine days in idiopathic intracranial hypertension. The semaglutide EVOKE trials in Alzheimer's failed clinically despite modest biomarker improvements.